Epicardial adipose tissue volume is greater in men with severe psoriasis, implying an increased cardiovascular disease risk: A cross-sectional study

Ellis, Charles N.; Neville, Stephen; Sayyouh, Mohamed; Elder, James T.; Nair, Rajan P.; Guðjónsson, Jóhann E.; Ma, Tianwen; Kazerooni, Ella A.; Rubenfire, Melvyn; Agarwal, Prachi P.

doi:10.1016/j.jaad.2021.09.069

Cited by 15 publications

(21 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last decade, the awareness of psoriasis has shifted from an inflammation and immune-media cutaneous disorder to a systemic inflammatory and immune-media disorder ( Kamiya et al., 2019 ). The clinical study of Piaserico S, Ellis CN, and Lerman JB found that patients with psoriasis have larger epicardial adipose tissues and higher risk of coronary microvascular dysfunction, noncalcified coronary plaque burden, and high-risk plaque prevalence, which is aggravated by the progression of the psoriasis ( Piaserico et al., 2019 ; Ellis et al., 2021 ; Lerman et al., 2017 ). Coronary atherosclerosis represent atherosclerosis of psoriasis complication, which have become a focus of systemic treatment for psoriasis ( Osto et al., 2012 ; Torres et al., 2013 ).…”

Section: Discussionmentioning

confidence: 99%

Prediction and verification of the effect of psoriasis on coronary heart disease based on artificial neural network

Qi²,

Li³

et al. 2022

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prediction and verification of the effect of psoriasis on coronary heart disease based on artificial neural network

Qi²,

Li³

et al. 2022

Heliyon

View full text Add to dashboard Cite

“…Subsequently, 722 articles were excluded since their titles and abstracts were not relevant to the meta-analysis, leaving 39 studies for full-text review. Finally, after excluding nine studies through full-text review, 16 studies (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33) were included. The reasons for removing the nine studies are also presented in Figure 1.…”

Section: Studies Obtainedmentioning

confidence: 99%

“…As shown in Table 1, fifteen case-control studies (18)(19)(20)(21)(22)(23)(25)(26)(27)(28)(29)(30)(31)(32)(33) and one cross-sectional study (24), including 3,039 patients with psoriasis and 46,191 controls without psoriasis, were included in this meta-analysis. The studies were published between 2007 and 2022, and conducted in Germany, Brazil, China, Japan, Denmark, Portugal, United States, and Ireland.…”

Section: Characteristics Of the Included Studiesmentioning

confidence: 99%

“…However, previous studies evaluating the association of psoriasis and CAC have shown inconsistent results (17). Some studies have suggested a significant association between psoriasis and CAC (18)(19)(20)(21)(22)(23)(24), while others have not demonstrated an association (25)(26)(27)(28)(29)(30)(31)(32)(33). In this study, we performed a systematic review and meta-analysis to comprehensively evaluate the association of psoriasis and CAC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association between psoriasis and coronary artery calcification: A systematic review and meta-analysis

Luo²,

Liu³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundPsoriasis and atherosclerosis have overlapping pathophysiological mechanisms. However, the association between psoriasis and coronary artery calcification (CAC), a hallmark of atherosclerosis and a predictor of poor cardiovascular prognosis, remains to be determined. We performed a systematic review and meta-analysis to comprehensively evaluate the association between these related inflammatory conditions.MethodsObservational studies evaluating the relationship between psoriasis and CAC were retrieved by searching PubMed, Cochrane’s Library, and Embase databases. Presence of CAC was confirmed according to an Agatston’s Score >0 upon computed tomography examination. A random-effect model incorporating between-study heterogeneity was used to pool the results.ResultsSixteen studies involving 3,039 patients with psoriasis and 46,191 controls without psoriasis were included in the meta-analysis. All participants were without previously known cardiovascular diseases. Pooled results showed that psoriasis was associated with overall CAC [odds ratio (OR): 1.54, 95% confidence interval: 1.23–1.91, p < 0.001; I2 = 57%], after matching or adjusting the conventional cardiovascular risk factors. Subgroup analyses showed that study country, comorbidity of psoriatic arthritis, baseline Psoriasis Area and Severity Index, and duration of psoriasis (p for subgroup difference all >0.05) did not significantly affect the association of psoriasis and CAC. However, a stronger association was observed in younger patients (mean age <50 years, OR: 2.63, p < 0.001) compared to older patients (≥50 years, OR: 1.24, p = 0.02; p for subgroup difference <0.001).ConclusionPsoriasis is associated with CAC, and the association may be stronger in younger patients.

show abstract

“…Due to the chronic nature of psoriasis [1][2][3], the affected patients may experience several comorbidities (i.e., respiratory [4][5][6][7][8], cardiovascular [9][10][11][12][13] or gastrointestinal ones [14][15][16][17]) and therapy failures [18][19][20][21][22][23][24][25]. Thus, therapeutic strategies play a pivotal in limiting the psoriasis detrimental progression and the quality of life worsening.…”

Section: Introductionmentioning

confidence: 99%

Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

et al. 2022

View full text Add to dashboard Cite

Since psoriasis (PsO) is a chronic inflammatory disease, patients may experience a drug failure also with very effective drugs (i.e., secukinumab) and, consequently, dermatologists have two therapeutic options: switching or perform a combination therapy (rescue therapy) to save the drug that had decreased its efficacy. At the moment no studies focused on combination/rescue therapy of secukinumab, so we performed a 52-weeks multicenter retrospective observational study that involved 40 subjects with plaque psoriasis that experienced a secondary failure and were treated with combination therapy (ciclosporin (n = 11), MTX (n = 15), NB-UVB (n = 7) and apremilast (n = 7)). After 16 weeks of rescue/combination therapy, PASI and a DLQI varied respectively from 8 [7.0–9.0] and 13 [12.0–15.0], to 3 [2.8–4.0] and 3 [2.0–3.3]), suggesting a significant improvement of daily functionality and quality of life. Results were maintained at 52 weeks. No side effects were experienced during the study. Secukinumab remains a safety and effective drug for PsO patients also in the IL-23 and JAK inhibitors era. The rescue therapy is a valid therapeutic option in case of secukinumab secondary failure.

show abstract

Epicardial adipose tissue volume is greater in men with severe psoriasis, implying an increased cardiovascular disease risk: A cross-sectional study

Cited by 15 publications

References 60 publications

Prediction and verification of the effect of psoriasis on coronary heart disease based on artificial neural network

Prediction and verification of the effect of psoriasis on coronary heart disease based on artificial neural network

Association between psoriasis and coronary artery calcification: A systematic review and meta-analysis

Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching

Contact Info

Product

Resources

About